Oncology Institute Earnings Estimate
| TOI Stock | USD 3.58 0.00 0.00% |
Oncology Institute Revenue Breakdown by Earning Segment
By analyzing Oncology Institute's earnings estimates, investors can diagnose different trends across Oncology Institute's analyst sentiment over time as well as compare current estimates against different timeframes. The Oncology Institute's current Gross Profit Margin is estimated to increase to 0.21, while Gross Profit is projected to decrease to under 47.1 M. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Oncology Institute Earnings Estimation Breakdown
The calculation of Oncology Institute's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Oncology Institute is estimated to be -0.085 with the future projection ranging from a low of -0.09 to a high of -0.08. Please be aware that this consensus of annual earnings estimates for Oncology Institute is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.09 Lowest | Expected EPS | -0.08 Highest |
Oncology Institute Earnings Projection Consensus
Suppose the current estimates of Oncology Institute's value are higher than the current market price of the Oncology Institute stock. In this case, investors may conclude that Oncology Institute is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Oncology Institute's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 4 | 50.99% | 0.0 | -0.085 | -0.67 |
Oncology Institute Earnings History
Earnings estimate consensus by Oncology Institute analysts from Wall Street is used by the market to judge Oncology Institute's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Oncology Institute's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Oncology Institute Quarterly Gross Profit |
|
Oncology Institute Earnings per Share Projection vs Actual
Actual Earning per Share of Oncology Institute refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Oncology Institute predict the company's earnings will be in the future. The higher the earnings per share of Oncology Institute, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Oncology Institute Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Oncology Institute, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Oncology Institute should always be considered in relation to other companies to make a more educated investment decision.Oncology Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Oncology Institute's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-12 | 2025-09-30 | -0.11 | -0.14 | -0.03 | 27 | ||
2025-08-13 | 2025-06-30 | -0.12 | -0.15 | -0.03 | 25 | ||
2025-03-25 | 2024-12-31 | -0.08 | -0.143 | -0.063 | 78 | ||
2024-11-06 | 2024-09-30 | -0.06 | -0.1751 | -0.1151 | 191 | ||
2024-08-13 | 2024-06-30 | -0.1 | -0.17 | -0.07 | 70 | ||
2024-05-14 | 2024-03-31 | -0.12 | -0.22 | -0.1 | 83 | ||
2024-03-27 | 2023-12-31 | -0.11 | -0.21 | -0.1 | 90 | ||
2023-11-08 | 2023-09-30 | -0.13 | -0.19 | -0.06 | 46 | ||
2023-08-08 | 2023-06-30 | -0.17 | -0.19 | -0.02 | 11 | ||
2023-05-10 | 2023-03-31 | -0.17 | -0.33 | -0.16 | 94 | ||
2023-03-09 | 2022-12-31 | -0.18 | -0.25 | -0.07 | 38 | ||
2022-11-09 | 2022-09-30 | -0.18 | -0.25 | -0.07 | 38 | ||
2022-08-09 | 2022-06-30 | -0.11 | -0.09 | 0.02 | 18 | ||
null | null | null | null | null | 0 |
About Oncology Institute Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Oncology Institute earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Oncology Institute estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Oncology Institute fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -189.7 M | -180.2 M | |
| Retained Earnings Total Equity | -56.8 M | -59.6 M | |
| Earnings Yield | (3.21) | (3.05) | |
| Price Earnings Ratio | (0.32) | (0.31) | |
| Price Earnings To Growth Ratio | 0.02 | 0.02 |
Currently Active Assets on Macroaxis
When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.67) | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets | Return On Equity |
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.